Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 3047-3048

  Brooks, Jason V ^a   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; RIFAMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0031724157     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.3047     Document Type: Article

References (25)

1. Buchanan, R. J. 1997. Compliance with tuberculosis drug regimens: incentives and enablers offered by public health departments. Am. J. Public Health 87:2014-2017.
2. Burman, W. J., C. B. Dalton, D. L. Cohn, J. R. Butler, and R. R. Reves. 1997. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 112:63-70.
3. Caminero, J. A., J. M. Pavon, F. Rodriguez de Castro, F. Diaz, G. Julia, J. A. Cayla, and P. Cabrera. 1996. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax 51:1130-1133.
4. Chapuis L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med. 150:1355-1362.
5. Chaulk, C. P., K. Moore-Rice, R. Rizzo, and R. E. Chaisson. 1995. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 274:945-951.
6. Cohn, D. L., B. J. Catlin, K. L. Peterson, F. N. Judson, and J. A. Sbarbaro. 1990. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann. Intern. Med. 11 2:407-415.
7. Dhillon, J., and D. A. Mitchison. 1992. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am. Rev. Respir. Dis. 145:212-214.
8. Dick, J., M. Clarke, J. Tibbs, and H. Schoeman. 1997. Combating tuberculosis - lessons learnt from a rural community project in the Klein Drakenstein area of the Western Cape. S. Afr. Med. J. 87:1042-1047.
9. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 68:183-193.
10. Ellis, J. H., N. Beyers, D. Bester, R. P. Gie, and P. R. Donald. 1997. Sociological and anthropological factors related to the community management of tuberculosis in the Western Cape communities of Ravensmead and Uitsig. S. Afr. Med. J. 87:1047-1051.
11. Gonzalez-Montaner, L. J., S. Natal, P. Yongchaiyud, and P. Olliaro. 1994. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis. 75:341-347.
12. Heifets, L. B., P. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
13. Hirata, T., H. Saito, H. Tomioka, K. Sato, J. Jidoi, K. Hosoe, and T. Hidaka. 1995. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39: 2295-2303.
14. Iseman, M. D. 1996. Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control. Tubercle Lung Dis. 77:101.
15. Jabes, D., C. Della Bruna, R. Rossi, and P. Olliaro. 1994. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrob. Agents Chemother. 38:2346-2350.
16. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
17. Johansson, E., V. K. Diwan, N. D. Huong, and B. M. Ahlberg. 1996. Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Tubercle Lung Dis. 77:178-183.
18. Kelly, B. P., S. K. Furney, M. T. Jessen, and I. M. Orme. 1996. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2809-2812.
19. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
20. Nowak, R. 1995. WHO calls for action against TB. Science 267:1763.
21. Orme, I. M. 1988. Antimycobacterial activity in vivo of LM427 (rifabutin). Am. Rev. Respir. Dis. 138:1254-1257.
22. Pretet, S., A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, and A. T. Dinh-Xuan. 1992. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur. Respir. J. 5:680-684.
23. Valway, S. E., M. P. C. Sanchez, T. F. Shinnick, I. M. Orme, T. Agerton, D. Hoy, J. S. Jones, H. Westmorland, and I. M. Onorato. 1998. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculous. N. Engl. J. Med. 338:633-639.
24. Wilkinson, D., E. Anderson, G. R. Davies, A. W. Sturm, and K. P. McAdam. 1997. Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa. Trans. R. Soc. Trop. Med. Hyg. 91:87-89.
25. Wilkinson, D., G. R. Davies, and C. Connolly. 1996. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am. J. Public Health 86:1094-1097.